Brian Bostick1, Javad Habibi2, Lixin Ma3, Annayya Aroor2, Nathan Rehmer2, Melvin R Hayden2, James R Sowers4. 1. Division of Cardiovascular Medicine, Diabetes Cardiovascular Center, University of Missouri, Columbia, MO, USA; Department of Medicine, University of Missouri, Columbia, MO, USA; Harry S. Truman Memorial Veterans Hospital, Columbia MO, USA. 2. Department of Medicine, University of Missouri, Columbia, MO, USA; Harry S. Truman Memorial Veterans Hospital, Columbia MO, USA; Division of Endocrinology and Metabolism, Diabetes Cardiovascular Center, University of Missouri, Columbia, MO, USA. 3. Harry S. Truman Memorial Veterans Hospital, Columbia MO, USA; Department of Radiology, University of Missouri, Columbia, MO, USA. 4. Department of Medicine, University of Missouri, Columbia, MO, USA; Harry S. Truman Memorial Veterans Hospital, Columbia MO, USA; Division of Endocrinology and Metabolism, Diabetes Cardiovascular Center, University of Missouri, Columbia, MO, USA; Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO, USA. Electronic address: sowersj@health.missouri.edu.
Abstract
OBJECTIVE: Consumption of a high-fat/high-fructose Western diet (WD) is linked to rising obesity and heart disease, particularly diastolic dysfunction which characterizes early obesity/metabolic cardiomyopathy. Mounting evidence supports a role for inflammation, oxidative stress and fibrosis in the pathophysiology of metabolic cardiomyopathy. Dipeptidyl peptidase-4 (DPP-4) is a circulating exopeptidase recently reported to be elevated in the plasma of patients with insulin resistance (IR), obesity and heart failure. We hypothesized that a model of WD induced obesity/metabolic cardiomyopathy would exhibit increased DPP-4 activity and cardiac fibrosis with DPP-4 inhibition preventing cardiac fibrosis and the associated diastolic dysfunction. MATERIALS/ METHODS: Four-week-old C57BL6/J mice were fed a high-fat/high-fructose WD with the DPP-4 inhibitor MK0626 for 16 weeks. Cardiac function was examined by high-resolution cine-cardiac magnetic resonance imaging (MRI). Phenotypic analysis included measurements of body and heart weight, systemic IR and DPP-4 activity. Immunohistochemistry and transmission electron microscopy (TEM) were utilized to identify underlying pathologic mechanisms. RESULTS: We found that chronic WD consumption caused obesity, IR, elevated plasma DPP-4 activity, heart enlargement and diastolic dysfunction. DPP-4 inhibition with MK0626 in WD fed mice resulted in >75% reduction in plasma DPP-4 activity, improved IR and normalized diastolic relaxation. WD consumption induced myocardial oxidant stress and fibrosis with amelioration by MK0626. TEM of hearts from WD fed mice revealed abnormal mitochondrial and perivascular ultrastructure partially corrected by MK0626. CONCLUSIONS: This study provides evidence of a role for increased DPP-4 activity in metabolic cardiomyopathy and a potential role for DPP-4 inhibition in prevention and/or correction of oxidant stress/fibrosis and associated diastolic dysfunction.
OBJECTIVE: Consumption of a high-fat/high-fructose Western diet (WD) is linked to rising obesity and heart disease, particularly diastolic dysfunction which characterizes early obesity/metabolic cardiomyopathy. Mounting evidence supports a role for inflammation, oxidative stress and fibrosis in the pathophysiology of metabolic cardiomyopathy. Dipeptidyl peptidase-4 (DPP-4) is a circulating exopeptidase recently reported to be elevated in the plasma of patients with insulin resistance (IR), obesity and heart failure. We hypothesized that a model of WD induced obesity/metabolic cardiomyopathy would exhibit increased DPP-4 activity and cardiac fibrosis with DPP-4 inhibition preventing cardiac fibrosis and the associated diastolic dysfunction. MATERIALS/ METHODS: Four-week-old C57BL6/J mice were fed a high-fat/high-fructoseWD with the DPP-4 inhibitor MK0626 for 16 weeks. Cardiac function was examined by high-resolution cine-cardiac magnetic resonance imaging (MRI). Phenotypic analysis included measurements of body and heart weight, systemic IR and DPP-4 activity. Immunohistochemistry and transmission electron microscopy (TEM) were utilized to identify underlying pathologic mechanisms. RESULTS: We found that chronic WD consumption caused obesity, IR, elevated plasma DPP-4 activity, heart enlargement and diastolic dysfunction. DPP-4 inhibition with MK0626 in WD fed mice resulted in >75% reduction in plasma DPP-4 activity, improved IR and normalized diastolic relaxation. WD consumption induced myocardial oxidant stress and fibrosis with amelioration by MK0626. TEM of hearts from WD fed mice revealed abnormal mitochondrial and perivascular ultrastructure partially corrected by MK0626. CONCLUSIONS: This study provides evidence of a role for increased DPP-4 activity in metabolic cardiomyopathy and a potential role for DPP-4 inhibition in prevention and/or correction of oxidant stress/fibrosis and associated diastolic dysfunction.
Authors: Orly Vardeny; Deepak K Gupta; Brian Claggett; Stuart Burke; Amil Shah; Laura Loehr; Laura Rasmussen-Torvik; Elizabeth Selvin; Patricia P Chang; David Aguilar; Scott D Solomon Journal: JACC Heart Fail Date: 2013-12 Impact factor: 12.035
Authors: Vincent G Demarco; David A Ford; Erik J Henriksen; Annayya R Aroor; Megan S Johnson; Javad Habibi; Lixin Ma; Ming Yang; Carolyn J Albert; John W Lally; Caleb A Ford; Mujalin Prasannarong; Melvin R Hayden; Adam T Whaley-Connell; James R Sowers Journal: Endocrinology Date: 2012-11-09 Impact factor: 4.736
Authors: Rutger W van der Meer; Luuk J Rijzewijk; Hugo W A M de Jong; Hildo J Lamb; Mark Lubberink; Johannes A Romijn; Jeroen J Bax; Albert de Roos; Otto Kamp; Walter J Paulus; Robert J Heine; Adriaan A Lammertsma; Johannes W A Smit; Michaela Diamant Journal: Circulation Date: 2009-04-06 Impact factor: 29.690
Authors: Kalkidan Bishu; Anita Deswal; Horng H Chen; Martin M LeWinter; Gregory D Lewis; Marc J Semigran; Barry A Borlaug; Steven McNulty; Adrian F Hernandez; Eugene Braunwald; Margaret M Redfield Journal: Am Heart J Date: 2012-10-16 Impact factor: 4.749
Authors: Brian Bostick; Javad Habibi; Vincent G DeMarco; Guanghong Jia; Timothy L Domeier; Michelle D Lambert; Annayya R Aroor; Ravi Nistala; Shawn B Bender; Mona Garro; Melvin R Hayden; Lixin Ma; Camila Manrique; James R Sowers Journal: Am J Physiol Heart Circ Physiol Date: 2015-03-06 Impact factor: 4.733
Authors: Guanghong Jia; Javad Habibi; Annayya R Aroor; Luis A Martinez-Lemus; Vincent G DeMarco; Francisco I Ramirez-Perez; Zhe Sun; Melvin R Hayden; Gerald A Meininger; Katelee Barrett Mueller; Iris Z Jaffe; James R Sowers Journal: Circ Res Date: 2016-02-15 Impact factor: 17.367
Authors: Maria Elizabeth de Sousa Rodrigues; Mandakh Bekhbat; Madelyn C Houser; Jianjun Chang; Douglas I Walker; Dean P Jones; Claudia M P Oller do Nascimento; Christopher J Barnum; Malú G Tansey Journal: Brain Behav Immun Date: 2016-09-02 Impact factor: 7.217
Authors: Shawn B Bender; Jorge A Castorena-Gonzalez; Mona Garro; Constantino C Reyes-Aldasoro; James R Sowers; Vincent G DeMarco; Luis A Martinez-Lemus Journal: Am J Physiol Heart Circ Physiol Date: 2015-06-19 Impact factor: 4.733
Authors: Alexander J Whittam; Zeshaan N Maan; Dominik Duscher; Janos A Barrera; Michael S Hu; Lauren H Fischer; Sacha Khong; Sun Hyung Kwon; Victor W Wong; Graham G Walmsley; Ferdinando Giacco; Michael Januszyk; Michael Brownlee; Michael T Longaker; Geoffrey C Gurtner Journal: Transl Res Date: 2018-11-02 Impact factor: 7.012
Authors: Guanghong Jia; Javad Habibi; Vincent G DeMarco; Luis A Martinez-Lemus; Lixin Ma; Adam T Whaley-Connell; Annayya R Aroor; Timothy L Domeier; Yi Zhu; Gerald A Meininger; Katelee Barrett Mueller; Iris Z Jaffe; James R Sowers Journal: Hypertension Date: 2015-10-05 Impact factor: 10.190